Diabetes econonomy2 Amini Masoud 1397

Type 2 diabetes mellitus (T2DM) is a progressive diseaseAchieving glycemic control and controlling cardiovascular risk factors have been conclusively shown to reduce diabetes complications, comorbidities, and mortality.

Diabetes is a disease that hurts, disables and kills our loved ones Diabetes is a disease that hurts, disables and kills our loved ones. It is costly by many measures—lost work, decreased quality of life and increased medical bills. Spending on personal health care for diabetes is greater than spending for any other disease.

Diabetes is a major global health threat and the number of cases is rapidly increasing. Recent estimates suggest that the number of people with diabetes across the world will increase from 415million in 2015 to 642million by 2040.

The global cost of diabetes is set to almost double to $2 The global cost of diabetes is set to almost double to $2.5 trillion by 2030 finds research from King’s College London.

Most notably, the report revealed that the economic costs of diabetes increased 26 percent from 2012 to 2017, due to both the increased prevalence of the disease and the increased cost per person living with diabetes.

People with diagnosed diabetes incur average medical expenditures of ∼$16,750 per year, of which ∼$9,600 is attributed to diabetes.

The total estimated cost of diagnosed diabetes in 2017 is $327 billion, including $237 billion in direct medical costs and $90 billion in reduced productivity.

Indirect costs: $90 billion, including, Increased absenteeism ($3.3 billion). Reduced productivity while at work ($26.9 billion) for the employed population

Reduced productivity for those not employed ($2.3 billion). Inability to work as a result of disease related disability ($37.5 billion). Lost productive capacity due to early mortality ($19.9 billion).

Direct medical costs: $237 billion (57% of the total medical costs incurred by people with diabetes), including, Hospital inpatient care ($69.7 billion). Prescription medications to treat the complications of diabetes ($71.2 billion).

Together, these two direct costs account for 60 percent of the total amount. The remaining costs include: antidiabetic agents diabetes supplies physician’s office visits

Antidiabetic agents and diabetes supplies ($34.6 billion). Physician office visits ($30.0 billion). Nursing/residential facility stays ($6.4 billio

. Despite the approval of 40 new treatment options for type 2 diabetes since 2005 these therapies and approaches have not had a meaningful impact on the degree of glycemic control in a large subset of the population with diabetes

Annual spending on insulin per patient increased from $231 to $736 Annual spending on insulin per patient increased from $231 to $736. over the study period. By 2013, the per-patient spending on insulin was greater than the per-patient combined spending on other diabetes drugs, which was $502.

We mailed a survey to a national sample of 720 primary care physicians (PCPs) and 480 endocrinologists in 2016 (adjusted response rate, 41%). Physicians were asked how often their patients were unable to start a new diabetes medication in general, and, specifically, an SGLT2i, because it was too expensive

November 20, 2018 Global study predicts 20-percent rise in insulin use by 2030 — but half the world's diabetics who need it won’t get i

The average price of insulin analogs tripled between 2002 and 2013, from an average of $4.34/mL to $12.92/mL.[1] In 2017, Americans spent $31 billion on diabetes medications, $15 billion of which was for insulin.

خط فقر بالاتر از 3.5 میلیون تومان

The 2016 U.S. GDP per capita was $57,300.

In a national survey conducted in 2011, 11 In a national survey conducted in 2011, 11.4% of Iranian adults aged 25 to 70 years had diabetes

یک چهارم جمعیت کشور ما چاق هستند و ۶۰ درصد افراد جامعه ما فعالیت فیزیکی کافی ندارند. شیوع دیابت حدود ۱۰ درصد جامعه ما است. یک سوم جامعه ما فشار خون بالا و ۲۵ درصد چربی خون بالا دارند

Total annual direct costs of diabetic and control participants were $152.3 +/- 14.5 and $52.0 +/- 5.8, respectively, which is indicative of 2.92 times higher costs in diabetic patients.

The most expensive components of direct costs were medications and devices, and hospitalisation in diabetic patients (28.7% and 28.6%, respectively). Total indirect costs were $39.6 +/- 2.4 and $16.7 +/- 1.1 in diabetic and non-diabetic individuals.

Despite substantial advances in care, 33% to 49% of individuals with T2D miss glycemic, blood pressure, or cholesterol targets. Only 14% meet all 3 goals in addition to not smoking

Moreover, management of diabetes complications comprises the largest share of direct costs.8 It has been concluded that the direct and indirect annual health care costs for an Iranian patient with diabetes is about 2.5 times higher than a healthy Iranian citizen.8

Direct costs of T2D were estimated to be about 8 Direct costs of T2D were estimated to be about 8.7% of the total health expenditure in Iran.4

۱۵ درصد هزینه‌های سلامت صرف دیابت می شود وزیر بهداشت؛